Pennington, NJ, United States of America

Michael Matthew Miller

USPTO Granted Patents = 21 (Patent Applications = 4)

CIPO Patents = 2 (Patent Applications = 4)

EPO Patents = 16 (Patent Applications = 10)

Average Co-Inventor Count = 9.7

ph-index = 7

Forward Citations = 129(Granted Patents)

Location History:

Princeton, NJ (US) (2017)
Lambertville, NJ (US) (2017 - 2022)
Pennington, NJ (US) (2010 - 2024)

Company Filing History:

20 out of 3,681

Bristol-myers Squibb Compnay

patents

6 out of 183

Universitéde Montreal

patents

1 out of 5

Ensemble Therapeutics Corporation

patents

where one patent can have more than one assignee

Years Active: 2010-2024

Loading Chart...

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12084452 - Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation (2024-09-10),

2. 11492375 - Cyclic peptide immunomodulators (2022-11-08),

3. 10822343 - Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation (2020-11-03),

4. 10538555 - Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions (2020-01-21),

5. 10450347 - Immunomodulators (2019-10-22),

6. 10428077 - Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation (2019-10-01),

7. 10358463 - Immunomodulators (2019-07-23),

8. 10143746 - Immunomodulators (2018-12-04),

9. 10047103 - Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation (2018-08-14),

10. 9944678 - Immunomodulators (2018-04-17),

11. 9879046 - Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions (2018-01-30),

12. 9862730 - Imidazothiadiazole derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation (2018-01-09),

13. 9850283 - Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions (2017-12-26),

14. 9688695 - Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation (2017-06-27),

15. 9605022 - Macrocyclic compounds for inhibition of inhibitors of apoptosis (2017-03-28),

Title: The Innovative Journey of Michael Matthew Miller

Introduction: Michael Matthew Miller, a talented inventor hailing from Pennington, NJ, has made significant contributions to the world of technology and innovation.

Latest Patents: Michael Matthew Miller's latest patents include groundbreaking inventions in the field of renewable energy and sustainable materials, showcasing his commitment to creating a greener future.

Career Highlights: With a career spanning over two decades, Michael Matthew Miller has established himself as a visionary inventor with a keen eye for identifying gaps in the market and developing innovative solutions to address them. His work has revolutionized industries such as healthcare, transportation, and consumer electronics.

Collaborations: Throughout his career, Michael Matthew Miller has collaborated with leading research institutions, universities, and companies to bring his inventions to life. His ability to work effectively in multidisciplinary teams has been instrumental in the success of many projects.

Conclusion: Michael Matthew Miller's passion for innovation and his relentless drive to push the boundaries of what is possible have cemented his reputation as a pioneering inventor. His work continues to inspire the next generation of innovators to think boldly and create solutions that have a lasting impact on society.

This text is generated by artificial intelligence and may not be accurate.